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Abstract
Recently, an interest has developed in designing in biomaterials for medical ultrasonics that can
provide the acoustic activity of microbubbles, but with improved stability in vivo and a smaller
size distribution for extravascular interrogation. One proposed alternative is the phase-change
contrast agent. Phase-change contrast agents (PCCAs) consist of perfluorocarbons (PFCs) that are
initially in liquid form, but can then be vaporized with acoustic energy. Crucial parameters for
PCCAs include their sensitivity to acoustic energy, their size distribution, and their stability, and
this manuscript provides insight into the custom design of PCCAs for balancing these parameters.
Specifically, the relationship between size, thermal stability and sensitivity to ultrasound as a
function of PFC boiling point and ambient temperature is illustrated. Emulsion stability and
sensitivity can be ‘tuned’ by mixing PFCs in the gaseous state prior to condensation. Novel
observations illustrate that stable droplets can be generated from PFCs with extremely low boiling
points, such as octafluoropropane (b.p. −36.7°C), which can be vaporized with acoustic
parameters lower than previously observed. Results demonstrate the potential for low boiling point
PFCs as a useful new class of compounds for activatable agents, which can be tailored to the
desired application.
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1. Introduction
The ability to selectively trigger changes in the physical properties of a material or
compound has led to a number of innovations in biomedical technology. Many activatable
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‘intelligent materials’ and nanoparticles have been designed to respond to external stimuli
such as electric/magnetic fields, heat, light, and sound [1]. In the field of ultrasound medical
imaging, recent interest has focused upon the development of phase-change contrast agents
(PCCAs), which convert from a liquid to a gaseous state upon exposure to thermal and/or
acoustic energy [2]. Many of the unique applications proposed for PCCAs take advantage of
the volumetric increase that occurs during vaporization. Microscale droplets limited to flow
in the vascular space have been proposed for a number of techniques, including temporary
occlusion of blood vessels and enhancing cavitation activity [3–6]. PCCAs manufactured
with diameters in the 100-nm range may be able to diffuse out of the characteristically
‘leaky’ vasculature of many solid tumors before phase-transition [7], providing a means of
contrast-enhanced extravascular imaging, cell-specific targeting, drug delivery, and therapy
via ultrasound [8, 9, 10].
Currently, the only ultrasound contrast agents (UCAs) approved by the FDA for clinical
applications consist of lipid-coated microbubbles with gaseous perfluorocarbon (PFC) cores
[11]. The high molecular-weight gaseous PFC core is favored due to its low solubility,
which provides enhanced circulation lifetime. The significant difference in density and
compressibility between the gas-core and surrounding fluid makes these microbubbles
highly echogenic and readily detectable with an ultrasound imaging system [12, 13]. In
addition, the perfluorocarbon dose used for typical clinical and pre-clinical studies results in
few to no adverse bioeffects [14]. Though they are restricted to vascular flow due to size,
their potential use for echocardiography, vascular perfusion imaging, drug/gene delivery,
and enhancement of cavitation/thermal-based therapies has been studied extensively [15–
23]. Several groups have investigated alternative ultrasound contrast agents based on inert
liquid perfluorocarbon cores, and although the contrast provided is inherently less than that
of UCAs, they have some echogenicity due to a higher density and a lower speed-of-sound
than water and tissue [24, 25]. Like their gas-core counterparts, these emulsions are non-
toxic in small doses, but can be designed to have greater stability in circulation than typical
UCAs [13, 26].
Phase-change contrast agents can be considered a hybrid of the gas-core UCAs and the inert
liquid core droplets in that the perfluorocarbons selected have a boiling point near enough to
body or room temperature that they can be ‘tipped’ from the liquid phase to the highly
echogenic gas phase through the addition of thermal and/or acoustic energy. The result is a
dynamic, high-contrast agent with very low toxicity that can be activated with spatial and
temporal specificity [2, 27, 28]. Additionally, through the naturally high fluorine content of
PFCs or through incorporation of nanoparticles/fluorescent dyes, use of these agents can be
extended to other imaging modalities such as 19F MRI, optical fluorescence imaging, and
photoacoustic imaging [29–32]. PCCAs normally consist of droplets of liquid PFCs with
boiling points near body temperature, such as dodecafluoropentane (b.p. 29°C) or
perfluorohexane (b.p. 60°C), encapsulated in a lipid or polymer shell to optimize emulsion
stability. The Clausius-Clapeyron relation dictates that the phase-transition temperature of a
compound is inversely proportional to the pressure exerted on it. As droplet size diminishes,
the Laplace pressure exerted on the core due to radial curvature increases. Therefore, PCCA
droplets with micro- and nanoscale diameters may experience several atmospheres of
pressure in addition to ambient pressure on the PFC core and the ‘effective’ boiling point is
increased significantly. Using the Clausius-Clapeyron-derived Antoine vapor pressure
equation, Sheeran et al. recently proposed that the substantial increase in Laplace pressure
may allow for the generation of nanodroplets from decafluorobutane (DFB, b.p. = −1.7°C)
[33]. The resulting droplets would, in theory, require less ultrasound energy to trigger
vaporization than droplets composed of the most commonly-used PFCs – reducing the
chance of unwanted ultrasound-induced bioeffects. Proof-of-concept was demonstrated with
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phospholipid-stabilized microscale DFB droplets, which showed significantly reduced
vaporization thresholds compared to dodecafluoropentane and perfluorohexane.
Our group has recently demonstrated a unique technique of ‘microbubble condensation’ that
allows for the ability to generate nanoscale decafluorobutane PCCAs in a simple manner
[34]. By exposing pre-formed DFB UCAs to decreased ambient temperature and increased
ambient pressure, a condensation of the perfluorocarbon core occurs (Figure 1). As the DFB
core condenses, the increased Laplace pressure allows the droplets to remain in the liquid
state when exposed to the original ambient temperature and pressure until vaporization is
induced by thermal or acoustic energy.
Although it has been relatively unexplored in the literature, there is expected to be a tradeoff
between the stability of the resulting emulsions and the acoustic pressure required to induce
vaporization. Therefore, design of PCCAs from low boiling point perfluorocarbons for
biomedical applications requires the ability to balance the overall stability through
manipulation of factors such as ‘effective’ PFC boiling point and droplet size. In this study,
we explore the ability of the microbubble condensation technique to generate PCCAs from
perfluorocarbons with even lower boiling points than DFB, such as octafluoropropane (OFP,
b.p. −36.7°C), and the tradeoff between relative in vitro stability and vaporization thresholds
at both room and body temperature that results. Furthermore, we examine whether the
balance between thermal stability and sensitivity to ultrasound-induced activation can be
further manipulated by mixing different species of gaseous PFCs to a desired ratio prior to
condensation. This concept is similar to one proposed by Kawabata and colleagues for liquid
perfluorocarbons [35], however, it has not been previously shown to be possible with low
boiling point, gaseous PFCs. Finally, we investigate whether the encapsulating lipid shell is
preserved during the condensation process. Many groups have explored the ability to modify
the shell of gas-core UCAs to provide a means of tissue-specific targeting or drug/gene
delivery [18, 20, 36]. If the shell of condensed droplets remains after condensation, there is
promise for extending nanodroplets composed of low boiling point PFCs to new diagnostic/




Polydisperse decafluorobutane and octafluoropropane microbubbles were formulated by
dissolution of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-methoxy(polyethylene-glycol)-2000 (DSPE-PEG2000)
in a 9:1 molar ratio and a total lipid concentration of 1.0 mg/mL. All lipids were purchased
from Avanti Polar Lipids (Alabaster, AL) and perfluorocarbons purchased from Fluoromed
(Round Rock, TX). The excipient solution was comprised of phosphate-buffered saline
(PBS), propylene glycol, and glycerol (16:3:1). After adding 1.5 mL of the resulting solution
to a 3 mL glass vial, the headspace of the vial was gas-exchanged with each
perfluorocarbon. Samples containing a mixture of perfluorocarbons were prepared by first
filling a 30 mL syringe with DFB and OFP in a 1:1 ratio and then conducting a gas-exhange
of the headspace of a lipid-containing 3 mL glass vial with the perfluorocarbon mixture.
Microbubbles were formed via standard agitation techniques using a Vialmix shaker
(Bristol-Myers-Squibb, New York, NY).
2.2. Microbubble Condensation
2.2.1. Condensation Procedure—The 3 mL vials containing PFC microbubble samples
were immersed in a CO2/isopropanol bath controlled to a temperature between −5°C and
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−10°C and swirled gently for approximately 1 minute. The vials were connected to an
adjustable high-pressure air source and headspace pressure in the vial was increased until a
change in consistency was noted in the microbubble sample – indicating the onset of
condensation. The combination of propylene glycol, glycerol, and PBS prevented sample
freezing during the short exposure to reduced temperatures (a total of approximately 2
minutes). After condensation, the pressure source was removed from the vial, leaving a
pressure head on the solution until further use.
2.3. Sample Sizing
Microbubble sample size distributions were measured using an Accusizer 780 (Particle
Sizing Systems, Santa Barbara, CA), which was capable of measuring particles as small as
0.5 µm in diameter. Sample statistics were measured and averaged for 3 samples of each
polydisperse group (DFB only, OFP only, 1:1 DFB + OFP). Accusizer sample volumes were
typically on the order of 3 µL for bubble samples. Dynamic light scattering (Malvern Nano
ZS, Malvern Instruments Ltd., Malvern, Worcestershire, U.K.) was used to characterize
content at the nanoscale for droplet samples. Approximately 1.5 mL of each condensed
droplet sample was transferred to a cuvette by micropipette and the undiluted contents sized
for each. The Malvern Nano ZS was capable of measuring particles up to 6 µm in diameter.
2.4. Sample Stability
To determine the relative stability of PFC droplet emulsions, samples were transferred by
micropipette to a 3 mL syringe and capped with no gas headspace. The syringes were
exposed to either room temperature (22°C) or body temperature (37°C) by submerging the
syringe in a heated water bath. Instability in the sample due to ambient temperature should
manifest as the spontaneous phase-transition of the largest droplets in the sample (the least
thermally stable), resulting in bubbles at the microscale. To capture this instability, the
samples were sized using the Accusizer 780A at 10-minute intervals over the course of an
hour to determine changes in the size distribution as well as concentration. Three samples of
each group (DFB only, OFP only, 1:1 DFB + OFP) were measured at each temperature and
the resulting distributions averaged. To display the change in concentration concurrently, the
distribution at each time point was normalized and weighted relative to the peak
concentration over the entire test.
2.5. Ultrasonic Vaporization Thresholds
2.5.1. Experimental Apparatus—The acoustic setup used for these experiments was
similar to that described in earlier studies [33]. Briefly, an acrylic-lined, continuously
degassed water bath was mounted onto an inverted microscope (Olympus IX71, Center
Valley, PA). Depending on the experiment, the water bath temperature was either
maintained at 22°C or 37°C. The 100× (NA = 1.0) water immersion objective was interfaced
with a high-speed camera (FastCam SA1.1, Photron USA, Inc., San Diego, CA). Images and
videos captured during the experiments were analyzed using ImageJ software (NIH,
Bethesda, MD). The optical resolution of the system limited measurement of particles to
those greater than or equal to approximately 1 µm in diameter to maintain reasonable
accuracy. Solutions of droplets and bubbles were pumped through a nearly optically and
acoustically transparent cellulose tube with a 200 µm inner diameter (Spectrum
Laboratories, Inc., Greensboro, NC) using a custom-built manual injector that allowed for
precise spatial manipulation of the sample volume observed. The portion of the tube in focus
was manipulated by a 3-axis micropositioner (MMO-203, Narishige Group, East Meadow,
NY).
A spherically-focused transducer with a 7.5 MHz center frequency and focal length of ~5
cm (V321, Panametrics, Inc., Waltham, MA) was used to transmit acoustic pulses into
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droplet samples. Signals consisting of a 2-cycle sinusoid of adjustable amplitude at 8 MHz
(total insonification time of 250 ns) were provided using an arbitrary waveform generator
(AFG 3101, Tektronix, Inc., Beaverton, OR) and amplified approximately 60 dB using an
RF amplifier (A500, ENI, Rochester, NY) before being delivered to the transducer. For
optical-acoustic alignment, the focus of the transducer was positioned to be confocal with
the microscope objective focus by a calibrated needle hydrophone (HNA-0400, Onda Corp.,
Sunnyvale, CA). The range of transducer output pressures was calibrated at the focus to
determine the approximate pressures experienced by droplets in the field of view.
2.5.2. Microscale Droplet Vaporization Threshold—Based on preliminary studies
involving microbubble condensation [34], the majority of the droplets in each sample have
diameters in the hundreds of nanometers. However, the presence of optically resolvable
microscale outlier droplets enables simple measurement of individual droplet vaporization
thresholds, which is convenient for comparison of the thresholds between different
perfluorocarbons. Samples were first vented with a 20 G needle and diluted in PBS until
only a few droplets were visible on screen at any particular time. This was typically on the
order of 10X dilution, but varied from sample to sample based on the number of outlier
droplets present. The large outlier droplets, which rested near the bottom of the
microcellulose tube, were maintained in focus using the position manipulator. Ultrasound
pulses were delivered in pressure increments of approximately 55 kPa (rarefactional) with
approximately 1–2 s of rest time between each manual pulse trigger. The rarefactional
pressure that induced phase-transition in the droplet was recorded for correlation with
droplet diameter.
2.6. Shell Preservation
To create microbubbles incorporating fluorescent marker in the lipid shell, 2 µL of Vybrant
DiI cell-labeling solution (Invitrogen Molecular Probes, Eugene, OR) was added to the
previously described lipid solution. The headspace of the vial was gas-exchanged with DFB
and subsequently agitated to form microbubbles. Condensation of the microbubble sample
was performed with the techniques described above. Brightfield and fluorescent digital
micrographs were obtained before microbubble condensation using a 100X objective with a
fluorescence microscope (BX51, Olympus, Center Valley, PA) and Metamorph Basic
software (Molecular Devices, Sunnyvale, CA).
3. Results
3.1. Microbubble and Droplet Size Distributions
All microbubble samples showed similar distribution characteristics regardless of which
perfluorocarbon or perfluorocarbon mixture was selected for the core (Table 1), although
there was a significant increase in mean concentration for the 1:1 DFB + OFP microbubbles
compared to DFB microbubbles (p = 0.01 by student’s 2-sided unpaired t-test), and a
significant decrease in size for 1:1 DFB + OFP microbubbles compared to DFB and OFP
microbubbles (p = 0.01 and p = 0.05, respectively).
3.2. Droplet Size Distribution
Dynamic light scattering (DLS) showed that the decrease in the size of the particles after
condensation resulted in droplet distributions primarily in the sub-micron range, which is
consistent with preliminary studies [34]. Samples containing DFB appeared to condense
with very little additional pressure (4–5 psi), while the 1:1 DFB + OFP mixture samples and
pure OFP samples required substantially more (25–30 psi and 45–50 psi, respectively).
Nanodroplets originating from DFB microbubble samples and 1:1 DFB + OFP mixture
microbubble samples both condensed to form peaks at 295 nm (Figure 2). The DFB
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nanodroplets had slightly higher average diameters than the samples created from a 1:1 PFC
mixture (363 ± 161 nm and 296 ± 94 nm, respectively). Pure OFP samples did not show
sufficient stability to be sized by DLS, although the optical data and vaporization data (see
below) confirms the condensation of OFP into both microscale and nanoscale droplets.
3.3. Droplet Emulsion Stability
The content of each sample at the beginning of the 60-minute test period showed that the
mode particle size was near the lower sensitivity threshold of the Accusizer. This confirms
that the actual size distribution of the sample is best represented by the sub-micron sizing
(DLS). The Accusizer, however, allows for simple characterization of the change in
distribution and concentration over time of the content greater than 500 nm in diameter.
Because the largest content in the phase-change emulsions is the least stable, the greatest
change in distribution and concentration over time should occur in the upper portion of the
sample distribution.
DFB exhibited remarkable stability in vitro at both temperatures, with a preservation of
distribution characteristics (Figure 3a,b) and no significant change in mean concentration
(Figure 4a,b) over the period. The PFC mixture samples showed a general preservation of
distribution characteristics (Figure 3c), but a 17% drop in mean concentration over the time
period at 22°C (p = 0.05, Figure 4a). At 37°C, the PFC mixture samples showed a 45%
decrease in mean concentration over the test period (p = 0.03, Figure 4b), and an increase in
the content between 3–10 µm was observed in the distribution profile (Figure 3d). OFP
samples showed significant instability at both temperatures. At both 22°C and 37°C, an 82%
decrease in mean concentration was observed over the time period (p = 0.04 and p = 0.01,
respectively, Figure 4a,b), although the decrease in concentration was more gradual over
time in the 22°C case. At 37°C, OFP samples decrease to their final concentration with the
first 10–20 minutes, and a corresponding increase in the content between 3 and 10 µm was
observed in the distribution profile (Figure 3f).
Droplet Vaporization Thresholds
3.3.1. Microscale Droplet Thresholds: Diluting droplet samples in PBS allowed
microscale outlier droplets to be isolated and vaporized individually (Figure 5). By exposing
20–30 droplets of each PFC to acoustic pressure, the peak rarefactional pressure that
initiated droplet vaporization could be mapped against droplet diameter to observe general
trends in vaporization thresholds (Figures 6 and 7). Results show that both perfluorocarbon
boiling point and ambient temperature greatly influenced the rarefactional pressure needed
to vaporize droplets, as expected, and that the vaporization pressure generally increased with
decreasing diameter in the small range tested. Additionally, a droplet core composed of a
mixture of perfluorocarbons resulted in droplets with vaporization thresholds between each
of the ‘pure’ perfluorocarbons (Figure 7).
3.3.2. Shell Preservation: Brightfield and fluorescence microscopy results showed that the
DiI-labeled encapsulating lipid shell was present after the condensation technique (Figure
8). Although this can be expected, it has not been previously illustrated, and is important for
future incorporation of therapeutic and targeting agents.
4. Discussion
This report demonstrates the extent to which a new class of low boiling point
perfluorocarbons can be manipulated with regard to stability and vaporization thresholds in
order to design phase-change ultrasound contrast agents with desirable properties. Perhaps
the most surprising result of these studies was that OFP, which comprises the PFC gas-core
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of the commercial UCA Definity™(Lantheus Medical Imaging, Inc., USA) [11], can be
condensed to form droplets that exhibit some stability at 22 °C - nearly 60 °C above its
normal boiling point of −36.7 °C. Furthermore, OFP droplets as large as 5–8 µm were able
to be optically resolved and vaporized (Figure 7). Once exposed to physiological
temperatures, however, the upper distribution of OFP emulsions represented by the
Accusizer show rapid spontaneous vaporization. While this may be unfavorable for most
PCCA applications where only ultrasonic activation is desired, it may be useful for creating
ultrasound contrast agents that vaporize immediately upon injection.
Both the sizing and concentration data over the course of the 1-hour test period revealed the
remarkable stability of DFB droplets when exposed to both room and body temperature in
vitro. In contrast, the portion of the OFP samples registered by the Accusizer were greatly
sensitive to both room and body temperature – showing rapid changes in the size
distributions and in concentration. Samples composed of 1:1 mixtures of OFP and DFB
showed generally favorable stability at room temperature with regard to both distribution
and concentration. Once exposed to body temperature, the samples retained the distribution
profiles, although the concentration dropped at a much faster rate than at room temperature.
These results highlight the expected relationship between general thermal stability and PFC
boiling point, including the effect of modulating the boiling point by mixing
perfluorocarbons. The thermal stability of droplets with diameters smaller than 500 nm (not
registered by the Accusizer) for all PFC compositions requires further investigation. For
example - while the portion of OFP samples greater than 500 nm appeared generally
unstable, it is possible that droplets in the 100–300 nm range may be sufficiently stable for
use at body temperature as a result of the increased Laplace overpressure. If so, then future
refinement of the size distribution to isolate this small content along with optimization of the
shell composition may sufficiently stabilize OFP samples to remain in the liquid state upon
injection. Additionally, the droplet samples in the present study were measured under
atmospheric pressure, and so the higher in vivo pressures may further stabilize circulating
and extravasated droplets.
A common convention in measuring acoustic output is to normalize the peak rarefactional
pressure (in MPa) by the square root of the US frequency (in MHz) – termed the
‘mechanical index’ (MI). Typical clinical diagnostic ultrasound machines are designed with
a maximum MI of 1.9 or less to reduce the likelihood of inertial cavitation and unwanted
bioeffects, although it is suggested that contrast-enhanced diagnostic imaging be performed
at much lower MIs. In this study, all microscale droplets were vaporizable at both room
temperature and body temperature using very short pulses (2 cycles) and with mechanical
indices less than 1.9 (approximately equivalent to 5.4 MPa at 8 MHz). The trends confirm
the inverse relationship between PFC boiling point and droplet vaporization threshold as
well as the expected inverse relationship between ambient temperature and droplet
vaporization threshold. Microscale DFB droplets were vaporized at pressures near 2 MPa
(MI of approximately 0.71) at body temperature (Figure 6), which is nearly 30% lower than
the pressures needed to vaporize at 5 MHz obtained from a previous study [33]. Although
the acoustic pulse lengths were slightly different in this study than the previous, decreasing
vaporization pressure as a function of increasing US frequency has been reported previously
in the literature and is confirmed here [3, 37]. Microscale OFP droplets could be vaporized
with pressures on the order of 0.5 MPa (MI of approximately 0.18) at body temperature. In
many applications, it may be preferable to perform investigatory imaging at low pressures
and vaporize injected PCCAs at a desired point using an ‘activation pulse’ of higher
pressure. For these purposes, the low vaporization threshold of microscale OFP droplets
may be unsuitable, and droplets composed of a mixture of PFCs or pure DFB may be more
appropriate.
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The concept of mixing liquid perfluorocarbons to modulate emulsion properties was initially
proposed by Kawabata and colleagues [35]. This study is the first to show that stability and
activation energy of emulsions can be modified by applying a similar concept to gaseous
perfluorocarbons prior to microbubble condensation. As shown in Figure 7, droplets
composed of a mixture of PFCs were vaporized at pressures between those required to
vaporize ‘pure’ droplets of either OFP or DFB, similar to the stability characteristics
observed (Figures 3 and 4). Although a significant amount of variation is present in the
thresholds, no overlapping points occurred between the perfluorocarbon groups, which
suggests that the PFCs were miscible and could be condensed to form a mixed droplet.
It is expected that the acoustic field near the bottom of the microcellulose tube is complex
due to interaction with the tube itself [38]. This may explain some of the variability present
in the droplet vaporization thresholds, as the microscale droplets rested on the tube prior to
vaporization. It may also be possible that the tube damped the pressure experienced by the
droplets, and that the actual pressures used to vaporize were lower than those reported here.
Additionally, it was noted during testing that very slight changes in transducer position
could yield significant changes in the reported vaporization threshold for microscale
droplets. This variation in transducer alignment can be seen in the values reported for both
DFB and OFP droplets at room temperature in Figures 6 and 7, where the trends appear to
be shifted upward to some degree in the latter image because they were collected under a
slightly different alignment. To ensure this source of variation did not influence conclusions
drawn regarding the efficacy of PFC mixing or relative vaporization energy, each figure
represents data collected on the same day under the same alignment conditions.
Measuring droplet vaporization thresholds for microscale droplets is convenient to compare
the general influence of factors such as PFC choice and temperature. Evaluating appropriate
vaporization pressures for nanoscale droplets, on the other hand, is confounded by their
inability to be individually resolved optically. In this study, the presence of microscale OFP
droplets implies the presence of nanoscale OFP droplets, although the samples were too
unstable to prove this by DLS. To verify the expected presence of vaporizable nanoscale
OFP droplets, a sample of OFP droplets was diluted 50% in PBS and exposed to an acoustic
rarefactional pressure of 1.1 MPa (MI of approximately 0.4) at 37°C (Figure 9). This
pressure was selected based on being approximately twice the pressure required to vaporize
microscale droplets. The resulting bubbles, which were between 1 – 5 µm, confirm the
presence of vaporizable sub-micron OFP droplets as small as 200–300 nm by ideal gas law
estimations [33, 39]. Future studies will be needed to more precisely define the appropriate
pressure levels needed to activate sub-micron content present in the samples both in vitro
and in vivo.
Results showing preservation of the lipid shell demonstrate the possibility to simply
incorporate elements such as tissue-specific targeting ligands, genes, or drugs by including
them at the microbubble state and then condensing to form the modified droplets. Few
studies to date have explored PCCAs capable of gene delivery or active tissue targeting prior
to vaporization. In our initial studies of DFB nanodroplets, a cationic lipid shell was used
that could be made to carry gene vectors [34]. Incorporating ligands that target cellular
markers of angiogenesis could result in ultrasonically-activatable nanodroplets capable of
molecular imaging of the extravascular space.
The size of a PCCA also plays a key role in the relationship between thermal stability and
sensitivity to ultrasound. Previously described methods of controlling or altering size
distributions of PFC droplets have relied on microfluidic sorting, microfluidic droplet
generation, or filtering [3, 30, 40–44]. Because the size of a PFC droplet produced by
microbubble condensation is largely dependent on the initial microbubble size, the size
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distribution of PFC droplets could be tailored as desired by simply controlling the size
distribution of the initial microbubble samples through well-described techniques such as
differential centrifugation or microfluidics [45, 46]. Combining precursor microbubble size-
selection with PFC mixing may provide a means of highly-tuning droplet sample
characteristics to specific applications.
5. Conclusion
In this study, we have demonstrated proof-of-principle that it is possible to design PCCAs
from a variety of low boiling point PFCs that have not been previously considered. The
results show that a given droplet’s balance between stability and ‘vaporizability’ is a
tradeoff of several factors such as PFC composition and ambient temperature. Through the
methods presented and discussed here, it is conceivable that one could customize the droplet
characteristics (size, thermal stability, vaporization threshold) with a particular application
in mind. These results demonstrate the promise for low boiling point PFCs as a useful new
class of compounds for activatable contrast agents.
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Exposing pre-formed PFC microbubbles to decreased ambient temperature and increased
ambient pressure results in condensation of the gaseous core. The decreased size results in
an increased Laplace pressure, which serves to preserve the particle in the liquid state. Once
exposed to increased temperature and energy delivered via ultrasound, vaporization of the
droplet core results in a larger, highly echogenic gas microbubble.
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Dynamic light scattering results for various nanodroplet formulations (N=3 for each group).
Both DFB and 1:1 DFB + OFP droplets resulting from polydisperse bubbles showed peaks
at 295 nm in diameter.
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Perfluorocarbon droplet distributions in vitro over a 1-hour period: Pure decafluorobutane at
a) 22°C and b) 37°C; DFB + OFP mixture at c) 22°C and d) 37°C; and pure
octafluoropropane at e) 22°C and d) 37°C. The distribution at each timepoint was scaled to
the relative mean concentration (concentration-weighted) to simultaneously reflect changes
in concentration over the time period.
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Change in concentration over time for droplet samples of each perfluorocarbon at a) 22°C
and b) 37°C.
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A microscale droplet of OFP exposed to a 0.25 µs pulse at approximately 0.55 MPa
vaporizes to form a gas bubble approximately 5-fold larger
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Vaporization pressure for microscale DFB and OFP droplets at 22°C and 37°C. The
vaporization threshold increased with increasing boiling point and decreasing diameter for
the small range observed.
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Droplets composed of a mixture of PFCs vaporized at 22 °C with rarefactional pressures
between each of the composing PFCs – indicating condensation of the mixed gases resulted
in a miscible dual-PFC core. By adjusting the ratio of PFCs, the vaporization threshold may
be further ‘tuned’.
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Brightfield (a, c) and fluorescence (b, d) microscopy illustrating that the shell is preserved
when DiI-labeled DFB microbubbles (a, b) are condensed to the liquid state (c, d), the shell
is preserved through the change in volume. (note that the droplet in c–d did not result
directly from condensation of the precursor bubbles in a–b). Scale bar is 5 micrometers.
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OFP droplet sample exposed to a 0.25 0µs pulses pulse at 1.1 MPa initiated at t = 0 forms
bubbles in the 1 – 5 µm range, confirming the presence of viable nanoscale OFP droplets.
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DFB Only 1.12 ± 0.83 8.93×109 ± 2.28×109
OFP Only 1.10 ± 0.81 1.278×1010 ± 2.32×109
DFB + OFP 1.02 ± 0.64 1.582×1010 ± 2.73×109
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